Characterization of Melan-A reactive memory CD8+ T cells in a healthy donor by Voelter, Verena et al.
International Immunology, Vol. 20, No. 8, pp. 1087–1096
doi:10.1093/intimm/dxn066
ª The Japanese Society for Immunology. 2008. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
Characterization of Melan-A reactive memory CD81
T cells in a healthy donor
Verena Voelter1, Nathalie Rufer1, Severine Reynard1, Gilbert Greub2, Roger Brookes3,
Philippe Guillaume4, Frederic Grosjean4, Theres Fagerberg5, Olivier Michelin1,5,
Sarah Rowland-Jones3, Clemencia Pinilla6, Serge Leyvraz1, Pedro Romero4 and Victor Appay1,7
1Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
2Center for Research on Intracellular Bacteria, Microbiology Institute, CHUV and University of Lausanne, Lausanne, Switzerland
3Medical Research Council Laboratories, Banjul, The Gambia
4Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland
5Swiss Institute for Bioinformatics, Ge´nopode, Lausanne, Switzerland
6Torrey Pines Institute for Molecular Studies, San Diego, CA, USA
7Cellular Immunology Laboratory, INSERM U543, Avenir Group, Hoˆpital Pitie´-Salpeˆtrie`re, Universite´ Pierre et Marie Curie-Paris 6,
Paris, France
Keywords: cross-reactivity, melanoma, Mycobacterium, T lymphocytes, tumor immunity
Abstract
Melan-A specific CD81 T cells are thought to play an important role against the development of
melanoma. Their in vivo expansion is often observed with advanced disease. In recent years, low
levels of Melan-A reactive CD81 T cells have also been found in HLA-A2 healthy donors, but these
cells harbor naive characteristics and are thought to be mostly cross-reactive for the Melan-A antigen.
Here, we report on a large population of CD81 T cells reactive for the Melan-A antigen, identified in one
donor with no evidence of melanoma. Interestingly, this population is oligoclonal and displays a clear
memory phenotype. However, a detailed study of these cells indicated that they are unlikely to be
directly specific for melanoma, so that their in vivo expansion may have been driven by an exogenous
antigen. Screening of a Melan-A cross-reactive peptide library suggested that these cells may be
specific for an epitope derived from a Mycobacterium protein, which would provide a further example
of CD81 T cell cross-reactivity between a pathogen antigen and a tumor antigen. Finally, we discuss
potential perspectives regarding the role of such cells in heterologous immunity, by influencing the
balance between protective immunity and pathology, e.g. in the case of melanoma development.
Introduction
The discovery of genes encoding tumor antigens and the
subsequent characterization of tumor-associated T-cell epito-
pes have drawn attention on the importance of human T cells
in anti-tumor immunity. One human tumor antigen in particu-
lar has proven to be extremely informative, the melanocyte/
melanoma differentiation antigen known as Melan-A (for mel-
anoma antigen A) or melanoma antigen recognized by T cells
1 (MART-1), which was among the first human tumor antigens
to be cloned (1). The Melan-A/MART-1 gene encodes a 118
amino acid transmembrane protein, which contains an
immunodominant HLA-A2 restricted CTL epitope, mapped
to residues 26–35 (EAAGIGILTV). Remarkably, the screening
of tumor infiltrating lymphocyte populations revealed that
a vast majority contained T cells reactive for the Melan-A
peptide (2). The inclusion of a high affinity Melan-A peptide
(i.e. with a Ala27Leu substitution) into fluorescently labeled
HLA-A2–peptide tetrameric complexes enabled the identifi-
cation and tracking of Melan-A-specific T cells directly in pe-
ripheral blood (3). It became soon apparent that a high
proportion of HLA-A2-positive melanoma patients display
circulating tetramer positive cells with features of antigen-
experienced cells (4, 5).
The considerable analytical power of HLA-A2–ELA pep-
tide complexes led to the surprising finding of measurable
numbers (0.07–0.08% of CD8+ T cells) of tetramer+ lympho-
cytes in over 70% of HLA-A2 healthy individuals (4). Even
more surprising was the finding that these cells belonged to
the naive T-cell population, indicating that thymic selection
generates a high number of precursors recognizing the
self-HLA-A2/Melan-A antigen in humans (6). The ligands
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involved in the selection of this T-cell repertoire have not yet
been identified. Although accumulating evidence indicates
a central role for self-peptides in thymic selection, no
Melan-A mRNA expression has been reported in the thy-
mus. It is possible that this Melan-A-reactive T-cell pool
may be generated through recognition of unknown Melan-A
cross-reactive peptides expressed in the thymus. It is likely
that the fine specificity of healthy individuals HLA-A2/
Melan-A tetramer+ naive cells is not the Melan-A antigen
and that these cells may be better defined as Melan-A
cross-reactive (7).
We present here the unanticipated identification of a popu-
lation of Melan-A reactive memory CD8+ T cells in a HLA-A2
healthy individual. Functional and phenotypic analysis and
screening with Melan-A cross-reactive peptides derived from
combinatorial peptide library were employed in order to in-
vestigate the nature of this population, which appeared to
be highly cross-reactive, with reactivity for both pathogen
and tumor antigens.
Methods
PBMC samples
Samples were obtained from HLA-A2+ healthy volunteers or
Melan-A-vaccinated patients, as well as Mycobacterium
tuberculosis (MTB) infected Gambian donors. The relevant
local Institutional (in Lausanne, Switzerland or in Banjuls,
The Gambia) Review Boards and Ethics Committees ap-
proved this study. Blood samples were generally used fresh
within 4 h (for optimal functional assessment of the lympho-
cytes) or PBMCs were separated from heparinized blood
and cryopreserved for subsequent studies.
Reagents and flow cytometry
HLA–peptide tetrameric complexes (tetramers) were pro-
duced as previously described (8) and included the follow-
ing peptides: Melan-A ELAGIGILTV, flu matrix GILGFVFTL
and Mycobacterium VVAGIGILAI. Anti-TCR-BV antibodies
were purchased from Beckman Coulter (San Diego, CA,
USA) and all other antibodies from Becton Dickinson Phar-
mingen (San Diego, CA, USA). Stainings were usually per-
formed directly on whole blood or on thawed PBMC as
previously described (9). Samples were analyzed on a Bec-
ton Dickinson FACSCalibur or CANTO, after compensation
was checked using freshly stained PBMC. For intracellular
IFNc staining and CD107a mobilization assay, thawed cryo-
preserved PBMCs were stained with tetrameric complexes
(15 min at 37C) prior to activation. Cells were subsequently
incubated with specific antigens at 10 lM final concentration
and with anti-CD107a antibodies (7 ll) in RPMI 1640/10%
FCS and left for 6 h at 37C. Brefeldin A (Sigma, at 10 lg
ml1 final concentration) and Monensin (Sigma, at 2 lM final
concentration) were added during the second hour of incu-
bation. Non-activated PBMCs were stained with tetrameric
complexes for 15 min at 37C at the end of the incubation.
Cells were washed in PBS, 0.5 mM EDTA, 1% BSA, fixed and
permeabilized in FACSTM Permeabilization buffer (Becton
Dickinson) for 10 min. After washing, staining was performed
for 15 min at room temperature in the dark using a panel of
PerCP- or APC-conjugated antibodies. Cells were then washed
and stored in 5% formaldehyde at 4C until analysis.
Molecular analysis of tetramer positive cells
TCR analysis was performed on tetramer positive cells
sorted by flow cytometry as previously described (10).
Briefly, CD8+ T cells were enriched with a MiniMACS device
and stained with Melan-A tetramers. Five cell aliquots were
sorted directly into wells of different 96-V-bottom plates us-
ing a FACSVantage SE (Becton Dickinson), followed by
cDNA preparation, amplification and TCR BV22 spectratyp-
ing. PCRs were run using fluorescent probe labeled primers
specific for the BV22 subfamily and for the BC chain. Fluo-
rescent run-off products and fluorescent DNA weight
markers were loaded on sequence gel in an automated se-
quencer (ABI Prism, Applied Biosystems). Sequencing of
the PCR product including the CDR3 region was then per-
formed using the same primers.
Peptide collection and Elispot assays
Decapeptides predicted to be stimulatory to Melan-A-
specific CD8+ T cells are ranked using a scoring matrix gen-
erated from data previously obtained by screening an
amidated C terminus decapeptide positional scanning syn-
thetic combinatorial peptide library screening (PS-SCL) with
one high avidity Melan-A-specific CTL clone (expanded
in vitro from melanoma patient PBMC) in a functional chro-
mium release assay (11). Briefly, a Z-scoring matrix was
generated using the average and standard deviation of the
percentage of specific lysis values of multiple experimental
data obtained for each mixture defined with one of 18 natu-
ral L-amino acids in each of the 10 positions of the decamer
library (12). Based on the assumption of independent and
additive contribution of the individual amino acids at each
position of a peptide to the peptide’s activity, the score of
each individual peptide was calculated by adding individual
stimulatory values of the composing amino acids. A program
was designed to use the matrix to score all overlapping
decapeptides contained in the GenPept protein database
(ftp://ftp.ncicfr.gov/pub/genpept) and thus identify sequences
with the highest predicted stimulatory scores (12). Individual
peptides were synthesized at Mixture Science Inc. (San
Diego, CA, USA) by the simultaneous multiple peptide
synthesis method. Purity and identity of each peptide were
characterized using an electrospray mass spectrometer inter-
faced with a liquid chromatography system. Single or pooled
synthetic peptides were used at a concentration of 10 lM in
IFNc enzyme-linked immunospot (Elispot) assays on PBMC
(1.5 105 cells per well) to define CD8+ T-cell responses di-
rectly ex vivo, as previously described. IFNc Elispot kits were
purchased from Diaclone Biotest. PHA was always included
as a positive control. Spots were counted with an automatic
reader (Bioreader 2000; BioSys GmbH). Assays were per-
formed in duplicates that showed good similarity.
Generation of Melan-A specific T-cell clones and cytotoxic
assays
Tetramer+/BV22+ CD8+ T cells were sorted using a FACS-
Vantage, cloned by limiting dilution and expanded with PHA
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and allogenic irradiated feeder cells in medium containing
150 U ml1 human recombinant IL-15 (hrIL-15). Subse-
quently, they were periodically (every 3–4 weeks) re-stimu-
lated with PHA, irradiated feeder cells and hrIL-15. Clones
were tested by tetramer and BV22 staining and then for
CDR3 region length and for TCR sequence. Chromium re-
lease experiments were performed as previously described.
Target cells (1000 cells per well) were T2 cells (A2+/Melan-
A) for peptide titration assays and the melanoma cell lines
Me 275 (A2+/Melan-A+), Me 260 (A2/Melan-A+) and NA8
(A2+/Melan-A) for tumor cell recognition assays.
Structural predictions of the VVA-HLA-A2 epitope
An ab initio method has been designed to theoretically pre-
dict the structure of peptides bound to the MHC class I mol-
ecule from the amino acid sequences alone (13). This
method is composed of two steps. First, the peptide confor-
mational space in the MHC environment is sampled. Sec-
ond, the conformers are evaluated by using a combination
of clustering and energy/entropy calculations. The conforma-
tional sampling was performed using a simulated annealing
protocol in which 1000 heating–cooling cycles were com-
pleted. The CHARMM molecular modeling program and the
allatom CHARMM 22 protein parameter set were used to
perform the simulated annealing protocol. At the end of each
cycle, a conformation of the peptide in the MHC molecule
was kept after energy minimization. The simulations were
performed in vacuum, using a distance-dependent dielec-
tric constant that accounts in part for the solvent screening
of the electrostatic interactions. For long-range non-bonded
interactions, an atom-based force switching was applied
from 14 to 15 A˚. During the entire simulation, the MHC mole-
cule was kept fixed, but no constraints were applied to the
peptide. For the evaluation of the conformers, clustering
according to geometric similarities was performed. Using
additional energy and entropy calculations, involving solva-
tion-free energies computed with the Poisson–Boltzmann
continuum models, the mean effective energy and the con-
formational free energy of clusters were computed. The final
conformation, i.e. the prediction, was chosen as the center
of the lowest conformational free energy cluster.
Results
High frequency of Melan-A tetramer+ CD8+ T cells in one
healthy donor
During the screening of a large number of HLA-A2 healthy
donors to study and expand Melan-A tetramer positive naive
CD8+ T cells (14), we came across a single donor (BC26)
who displayed a remarkable Melan-A tetramer-positive
CD8+ T-cell population, representing 1.35% of the whole
CD8+ T cells. The frequency of this population was 20 times
superior to the mean frequency (0.078% of CD8 T cells,
n = 76) measured in the majority of healthy donors (Fig. 1A).
In addition, tetramer staining of these cells yielded a well-
defined population (in contrast with smeary stains from com-
mon healthy donor populations), resembling memory cell
populations, like Flu-specific CD8+ T cells, as seen in the
same donor (Fig. 1B).
BC26 Melan-A tetramer+ CD8+ T cells display a memory
phenotype
Phenotypic analysis revealed that the vast majority of these
cells were antigen experienced (CCR7/CD45RA), unlike
populations found in HLA-A2 healthy donors, but alike Flu-
specific CD8+ T cells found in the same donor (Fig. 1C). To
confirm that BC26 Melan-A tetramer-positive cells were in-
deed antigen-experienced cells, TCR repertoire analysis of
this population was performed. Using a panel of anti-TCR
antibodies, we observed that this population was highly oli-
goclonal with the great majority of the cells displaying BV22
and AV2.2 expression (Fig. 1D). This is similar to Melan-A-
specific CD8+ T cells that usually express AV2.1 and are
stained with the anti-AV2.2 specific mAb [PR, unpublished
observations and (15)]. Interestingly, BV22 spectratyping
analysis performed on Melan-A tetramer-sorted BC26 cells
and subsequent sequencing of the CDR3 region revealed
that this BV22+ population represented a single clonotype
(Fig. 1E and F) and therefore that the majority of BC26
Melan-A tetramer-positive CD8+ T-cell population was one
expanded clone. CD27/CD28 expression showed that these
cells were still at an early stage of differentiation (i.e. mostly
CD27+/CD28+) (16) (Fig. 1C). They appeared to be armed
cytotoxic T cells, expressing low levels of perforin as well as
granzymes A and B, again in clear contrast with Melan-A
tetramer-positive CD8+ T cells from common healthy donors
(Fig. 1C).
BC26 Melan-A tetramer+ CD8+ T cells are poorly
responsive to Melan-A
The occurrence of Melan-A tetramer-positive CD8+ T cells with
such characteristics is usually observed in tumor infiltrated
lymph nodes and associated with advanced melanoma dis-
ease. The presence of an unidentified melanoma tumor in this
donor was considered but excluded after thorough clinical
evaluation. Moreover, the donor presented no sign of vitiligo
or of cancer development over a follow-up period of 4 years.
Although unreported to date, one possibility for the presence
of this Melan-A-reactive CD8+ T-cell population in the absence
of clinical melanoma evidence may actually be related to a
particular ability of these cells to control effectively melanoma
growth following initial cancer development and T-cell priming.
This would imply in part that this CD8+ T-cell population dis-
plays robust functional capacity in order to halt tumor growth.
Functional responsiveness of these cells was assessed
through IFNc secretion and CD107a mobilization (as a marker
of lytic degranulation), following short-term stimulation with the
Melan-A peptide. However, to our disappointment, BC26
Melan-A tetramer-positive cells showed a sub-optimal respon-
siveness compared with Flu-specific CD8+ T cells from the
same donor as well as to Melan-A-specific CD8+ T cells from
a Melan-A-vaccinated melanoma patient, for same peptide
concentrations (Fig. 2). This observation was repeated at dis-
tinct times. This result, together with the prolonged lack of
melanoma evidence, eventually raised doubts as regards the
fine specificity of this population. We started to consider a sec-
ond possibility: that these cells may actually be specific for
another antigen than Melan-A (consistent with their presence
in the absence of melanoma).
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Preferential recognition of a Mycobacterium peptide by BC26
CD8+ T cells
To identify the antigen of interest, we decided to use a collec-
tion of Melan-A cross-reactive peptides derived from a
PS-SCL. The PS-SCL approach has previously led to the
successful study of T-cell specificity and the identification of
biologically active peptides (17–21). A collection of 100 pep-
tides, retrieved from self or pathogen protein databases by
means of biometric score matrix analysis of a PS-SCL (com-
posed of trillions of decapeptides covering all possibilities
of amino acids at each position of nonapeptides or decap-
eptides, tested in pools for their ability to stimulate a cytolytic
response from a high avidity Melan-A-specific CTL clone
in a functional assay), with ranked reactivity for Melan-A-
specific TCR (11, 22, 23), was used to screen BC26 PBMC
by IFNc Elispot directly ex vivo. Four out of the 100 selected
peptides elicited a response, but only one peptide (i.e. 91)
induced a response that was significantly higher than the
optimized Melan-A peptide ELA (Fig. 3A). BC26 Melan-A
tetramer-positive cells presented a stronger recognition effi-
cacy for this peptide than for ELA as assessed in peptide
titration assays (Fig. 3B), as well as a good functional re-
sponsiveness following stimulation with this peptide
(Fig. 3C) (in contrast to the ELA response, Fig. 2A). In addi-
tion, we were able to generate peptide–HLA-A2 tetrameric
complexes with peptide 91. These tetramers yielded a robust
staining of BC26 PBMC, brighter than with classic Melan-A
tetramers, resembling more, in terms of MFI, Melan-A-
specific CD8+ T cells from a Melan-A peptide-vaccinated
patient (Fig. 3D). In the same line, while double Melan-A
tetramer staining (PE/APC) led to co-staining of the BC26
population, Melan-A tetramer staining was lost when per-
formed concurrently with tetramer 91 staining (Fig. 3E).
Overall, this suggests that the avidity of BC26 Melan-A
tetramer-positive population TCR is much higher for peptide
91 than for ELA, making this peptide a good candidate for
the specificity of BC26 population.
BC26 responsiveness for purified protein derivative
Peptide 91 (VVA) is derived from a probable export or mem-
brane protein of 165 amino acids from Mycobacteria accord-
ing to genomic databases (ORF Rv1382). It is found at least
in MTB and Mycobacterium bovis, but may also be present
in other Mycobacteria (that have not been sequenced yet).
Ensuing these results, a chest X-ray scan and a Mantoux tu-
berculin skin test were performed on BC26, but they did not
Fig. 1. Identification of a Melan-A tetramer+ memory CD8+ T-cell population in one healthy donor. (A) Proportion of Melan-A tetramer+ T cells
within the CD8+ population of BC26 compared with other healthy donors. (B) Representative stainings of Melan-A tetramer+ CD8+ T cells for
BC26 and one healthy donor. Percentages of tetramer+ cells within the CD8+ T cells are shown. (C) Expression of differentiation markers
(CD45RA/CCR7/CD28/CD27) or cytotoxic factors (perforin, garnzymes A and B) on BC26 Melan-A tetramer+ CD8+ T cells compared with BC26
Flu-specific CD8+ T cells and Melan-A tetramer+ CD8+ T cells from one representative healthy donor. Percentages of cells present in quadrants
are shown. This phenotype was consistent in three different blood samples obtained over 3 years. (D) Expression of BV22 and AV2.2 by BC26
Melan-A tetramer+ CD8+ T cells. (E) BV22 spectratyping analysis performed on naive, whole antigen experienced and Melan-A tetramer+ CD8+
T cells FACS sorted from BC26 PBMC. (F) CDR3 sequence of the BV22+ Melan-A tetramer+ CD8+ T-cell clonal population.
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permit to conclude that this donor was infected with MTB. In-
terestingly, stimulation of BC26 PBMC with MTB protein
extracts [purified protein derivative (PPD)] yielded a clear
positive response (Fig. 4). Similar results were observed
both using intracellular cytokine and Elispot assays at two
distinct time points. However, since reactivity to PPD can be
observed not only in case of MTB infection but also in case
of infections with other Mycobacteria, BC26 PBMC reactivity
to MTB-specific proteins CFP-10 and ESAP-6 was tested
(24). Stimulation with these antigens did not lead to a clear
response (compared with responses obtained with a known
active MTB control), preventing us to conclude on MTB in-
fection with certainty. Overall, BC26 reactivity for PPD indi-
cates that BC26 has been infected with a pathogen
belonging to the Mycobacterium genus (i.e. MTB or environ-
mental Mycobacteria).
Cross-reactivity between Melan-A and Mycobacterium
peptides
To assess the antigen recognition efficacy of BC26 mostly
clonal population in more details, we generated and ex-
panded a clone in vitro expressing the TCR BV22-CDR3-
EPGLAREQ clonotypic sequence. Chromium release assays
were performed using this clone in comparison with a clone
derived from a Melan-A peptide-vaccinated patient (25, 26),
presenting a high avidity for the ELA peptide. Peptide titra-
tion assays confirmed the high recognition efficacy for pep-
tide 91 (as high as the recognition efficacy of the
vaccinated patient’s clone for ELA, with IC50 values in the
range of 1011 M) (Fig. 5A). Remarkably, its recognition effi-
cacy for the natural Melan-A antigen EAA was still relatively
good (and similar to the one of the vaccinated patient’s
clone, range of 109 M) (Fig. 5A). Most importantly, this
clone was able to recognize a melanoma tumor cell line that
expressed naturally the Melan-A antigen, in the same range
as the vaccinated patient’s clone (Fig. 5B), indicating that
the cross-reactivity of BC26 population for the Melan-A anti-
gen is significant. The homology of sequence between the
Melan-A antigen and peptide 91 is mostly located in the
core of the peptide (Fig. 5C). Modeling of the Mycobacteria
peptide and both the optimized and the natural Melan-A
peptides within the groove of the HLA-A2 molecule revealed
Fig. 2. Low recognition efficacy of BC26 Melan-A tetramer+ CD8+ T cells for the Melan-A peptide. Functional responsiveness (IFNc secretion
and degranulation) of Melan-A tetramer+ or Flu-specific CD8+ T cells from BC26 and Melan-A-specific CD8+ T cells from one Melan-A peptide-
vaccinated melanoma patient upon stimulation with cognate peptides (at 5 lM). IFNc production and CD107a up-regulation are shown on
tetramer-gated cells. Percentages of cells present in quadrants are shown.
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a remarkable homology of structure between these epitopes,
which explains this degree of cross-reactivity.
Discussion
The study of a large number of HLA-A2 healthy individuals
led to the identification of a remarkable population of Melan-
A reactive CD8+ T cells in one healthy donor (BC26). In order
to comprehend the nature of this population, we performed
a thorough investigation, which included the analysis of its
phenotype, clonality, functional responsiveness and the use
of Melan-A cross-reactive peptides to assess antigenic reac-
tivity. The unexpected memory phenotype displayed by the
population could suggest that the expansion of this popula-
tion may have been driven by a tumor, and let us speculate
that these cells may be able to drive control of tumor devel-
opment. However, this population eventually presented a poor
functional responsiveness to the Melan-A antigen, making
unlikely that it had a particular efficacy against the tumor, but
rather indicating that it may be cross-reactive for Melan-A.
In order to investigate further the potential specificity of this
population, we used a selection of Melan-A cross-reactive
peptides derived from a combinatorial peptide library:
screening of these peptides indicated that BC26 Melan-A tet-
ramer+ cells were highly reactive for a peptide derived from
a putative export or membrane protein from a Mycobacte-
rium, which presented a strong structural homology with the
Melan-A peptide. Although, it is tempting to think that this ap-
proach led to the identification of BC26 Melan-A tetramer+
cell cognate antigen, one cannot rule out the possibility that
the identified peptide may simply be another cross-reactive
mimotope. For instance, this would also be the case for three
other peptides from our library which could elicit responses
(although these were of lower magnitude). We therefore look
for evidence of Mycobacterium infection in the donor to sup-
port the possibility that this Melan-A tetramer-positive popula-
tion may have been generated as a result of such an
infection. Since the clinical diagnosis of latent Mycobacte-
rium infection is difficult, the detection of an immunological
memory (i.e. cytokine producing PBMC upon stimulation with
Mycobacterium-related antigens) is considered as the most
sensitive test available (27, 28). BC26 PBMC reactivity to
PPD indicates that this donor must have been infected with
a Mycobacterium at some point in her life. PPD-positive
Fig. 3. Identification of BC26 Melan-A tetramer+ CD8+ T-cell fine specificity. (A) Screening of peptides derived from a Melan-A-based
combinatorial peptide library analysis using BC26 PBMC. IFNc Elispot assays were performed to examine the reactivity of BC26 PBMC to the
ELA and EAA peptides as well as to the PS-SCL-derived peptide collection. Results are expressed in spot-forming units (background subtracted,
6standard deviation). *P = 0.013 with the non-parametric Mann–Whitney test. (B) Peptide titrations in IFNc Elispot assays (spot forming units/106
PBMC) to assess recognition efficacy of BC26 PBMC for peptide 91 (VVA) versus ELA (peptide 56 was used as a negative control). (C)
Functional responsiveness (IFNc secretion and degranulation) of BC26 CD8+ T cells upon stimulation with VVA (no stimulation or stimulation with
peptide 56 was used as controls). IFNc production and CD107a up-regulation are shown on tetramer-gated cells. Percentages of cells present in
quadrants are shown. (D) Staining of BC26 PBMC with VVA tetramers compared with ELA tetramer stainings on BC26 or one Melan-A peptide-
vaccinated melanoma patient PBMC. (E) Co-staining of BC26 cells with ELA/VVA, ELA/ELA and ELA/Flu tetramers.
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response can also be detected in individuals vaccinated with
the ‘bacille de Calmette–Gue´rin’ (BCG). However, no record
of BCG vaccination was found for this donor. Moreover, if
BCG vaccination had led to the induction of such Melan-A
cross-reactive cells, these cells would have been detected
in more HLA-A2 donors during the screening. Despite the
low prevalence of Mycobacterium infection, exposure of
BC26 to such pathogen may have been increased since
BC26 works as a nurse in an hospital. Responses to the
MTB-specific antigens, CFP-10 and ESAP-6, remained too
weak (borderline significance) to enable a definitive conclu-
sion regarding MTB infection. Seventy Gambian patients with
active MTB were screened with peptide 91 using IFNc Elispot,
but no significant response to this peptide was found (data
not shown), providing no further evidence of a link with MTB
infection. However, additional screening in different settings
may be required since this experimental setting may not be
optimal (i.e. different ethnic group, active MTB, unknown
HLA). Taken together, BC26 reactivity for PPD and for a My-
cobacterium-derived peptide (i.e. 91) suggests that BC26
has been infected with a pathogen belonging to the Myco-
bacterium genus (i.e. MTB or environmental Mycobacteria,
with which infections are rare and poorly studied), and that
its Melan-A tetramer-positive population might indeed be
specific for this pathogen. However, evidence (e.g. clear as-
sociation between 91 reactivity and Mycobacteria infection
in a large cohort) is lacking to support unequivocally this as-
sumption, so one cannot rule out the possibility that these
observations may only be coincidental and that the cognate
antigen that primed these cells still remains unknown.
TCR recognition of MHC–peptide complexes is central in
T-cell development, including thymic selection, survival of
naive T cells and differentiation into antigen-experienced
T cells. For long, it was commonly believed that TCR recog-
nition was highly specific, with an individual T cell being ca-
pable of only recognizing a particular peptide. Hence, TCR
cross-reactivity has often been considered as a rare event,
and its biological relevance questioned by scientists. How-
ever, increasing examples of pathogen-specific T cells rec-
ognizing cross-reactive epitopes within different proteins of
the same pathogen, proteins from closely related or totally
unrelated pathogens or even self-proteins have now been
documented in both human or murine settings (29–36). The
case presented in this study may illustrate further the possi-
bility of CD8+ T-cell cross-reactivity between pathogen and
tumor antigens.
Cross-reactive ability is thought to be valuable to the host,
considering the limited immunological space and T-cell num-
ber versus the large number of pathogenic antigens to
which one may be exposed over a lifetime (37). For in-
stance, Mason (38) calculated that a single T cell would
need to recognize many different peptides (e.g. up to 109)
Fig. 4. BC26 reactivity for Mycobacterium antigens. Representative CD69 expression and IFNc secretion upon stimulation with PPD and two
MTB-specific proteins by CD4+ T cells from BC26; one patient with known active MTB disease and one healthy donor control. Percentages of
CD69+/IFNc+ cells are shown.
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Fig. 5. Recognition efficacy and tumor recognition of BC26 CD8+ T-cell clone. (A) Recognition efficacy for peptide 91 as well as ELA or EAA was
tested in chromium release assays by peptide titrations. Peptide-pulsed T2 cells were used as targets for one CTL clone generated by FACS
sorting of tetramer+ T cells and subsequent in vitro expansion in the presence of IL-15, in comparison with one high avidity Melan-A-specific CTL
clone generated from a Melan-A-vaccinated donor [10:1 effector:target (E:T) ratio]. (B) Tumor recognition was tested for the EPGLAREQ clone by
cytotoxicity against Melan-A-expressing HLA-A2+ melanoma cell lines at different E:T ratios and in comparison with a high avidity Melan-A-
specific CTL clone. Melan-A-/HLA-A2+ or Melan-A+/HLA-A2 melanoma cell lines as well as EAA-pulsed cell lines were used as controls. (C)
Sequence alignment and structural prediction of the peptide 91 (yellow), ELA (black) and EAA (red) bound to the HLA-A2 molecule.
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in order for the T-cell repertoire to recognize the vast array of
possible different peptide–MHC antigens (e.g. up to 1017).
Cross-reactive T cells may thus be employed in immune
responses and mediate protective immunity. While T-cell
clones characterized by a high affinity TCR interaction with
a given peptide–MHC complex are usually less cross-reactive
than lower avidity T cells (39), we identified here a CD8+
T-cell clone presenting a high avidity for a Mycobacterial an-
tigen as well as a relatively good avidity for a melanoma an-
tigen. Although the functional capacity of this clone ex vivo
was weak in response to the Melan-A peptide, the level of
cross-reactivity for this antigen was sufficient to enable the
recognition in vitro of melanoma antigen naturally expressed
by tumor cells. The potential role that these cross-reactive
memory T cells could play in heterologous immunity is obvi-
ously fascinating, and would deserve further investigation
to see if these cells could mediate effector functions in case
of melanoma development and influence the balance be-
tween protective immunity and disease progression. Since
the phenomenon of cross-reactivity occurs here at the level
of a memory T-cell population (in contrast to naive T-cell
populations in other HLA-A2 healthy donors), their influence
might be particularly relevant as memory cells are present
at a high frequency and are easier to activate than naive
cells (40). The balance between specificity and degeneracy
of T-cell antigen recognition may represent a compromise
that permits the host to respond to a multitude of pathogens
as well as accommodating these numerous large memory
pools in a finite immune system.
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